NEW LAUNCHES IN US AND SWITZERLAND

THIRD QUARTER OF 2013

•    NET SALES amounted to MSEK 24.1 (20.8).
•    OPERATING PROFIT totalled MSEK 4.5 (4.0).
•    PROFIT AFTER TAX amounted to MSEK 3.7 (2.9).
•    PROFIT AFTER TAX PER SHARE was SEK 0.41 (0.32).
•    CASH FLOW amounted to MSEK 4.2 (neg: 1.8).

ACCUMULATED 2013

•    NET SALES amounted to 76.1 MSEK (73.4).
•    OPERATING PROFIT totalled MSEK 15.1 (14.6).
•    PROFIT AFTER TAX amounted to MSEK 12.4 (11.4).
•    PROFIT AFTER TAX PER SHARE was SEK 1.36 (1.25).
•    CASH FLOW amounted to MSEK 4.1 (9.9). Probi paid dividends of MSEK 6.8
(6.8).

INFORMATION FOR COMPARATIVE PURPOSES:

The accumulated comparative figures for the year-earlier period have been
impacted by contractual changes pertaining to NextFoods and Danone. Adjusted for
these changes, which totalled MSEK 6.3, net sales increased MSEK 9.0, from MSEK
67.1 to MSEK 76.1 and operating profit increased MSEK 6.8, from MSEK 8.3 to MSEK
15.1.

SIGNIFICANT EVENTS DURING THE THIRD QUARTER:

•    Probi signed an agreement with BioLife for the distribution of Probi
Digestis® in Malaysia.
•    Probi signed an agreement with Botanic Pharma for the distribution of Probi
Digestis® in Morocco.
•    Probi’s partnership with Health World in Australia was expanded to include
the launch of Probi Defendum®.
•    Vifor Pharma launched Probi’s digestive health capsules in the Swiss
market.

CEO’S COMMENTS:

”Probi reported a strong third quarter with a healthy increase in sales,
improved earnings and a strong cash flow. The positive trend is primarily driven
by growth in Consumer Healthcare. Net sales in this business area to date this
year have risen 28% compared with the corresponding period in 2012. The North
American market continues to account for a significant portion of this growth.
The first launch through the Viva 5 partnership took place in September and more
launches in the US are planned for later this year. Our gut health product has
now also been launched in Switzerland in partnership with Vifor Pharma,” says
Gun-Britt Fransson, interim CEO of Probi.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Gun-Britt Fransson, interim CEO, Probi, tel: +46 (0)46 286 89 74 or +46 (0)705
95 73 27, e-mail: gun-britt.fransson@probi.se
Niklas Brandt, CFO Probi, tel: +46 (0)46 286 89 26 or +46 (0)706 62 98 83, e
-mail: niklas.brandt@probi.se

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act. The information was submitted for publication on 22 October 2013 at 8:45
a.m.

This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.

ABOUT PROBI

Probi is a leading player in probiotic research and development of effective and
well-documented probiotics. The research areas are: the gastrointestinal tract,
immune system, metabolic syndrome and stress and recovery. Probi’s customers are
leading companies in the Functional Food and Consumer Healthcare segments. Total
income for 2012 was MSEK 100.4. Probi’s share is listed on Nasdaq OMX Stockholm,
Small Cap. Probi has approximately 5,000 shareholders. Read more on www.probi.se